Background: An autoimmune condition called alopecia areata produces temporary, non-scarring hair loss without destroying the hair follicle. Recently, alopecia areata has been treated with tofacitinib citrate, a Janus kinase 1/3 inhibitor, in addition to rheumatoid arthritis (AA). The outcomes of extended tofacitinib therapy for adult Indian patients with moderate-to-severe AA are reported.Materials and methods: Records for every patient assessed at a tertiary care center clinic with AA, AT, or AU were found between December 2022 and December 2023. Patients had to meet three requirements in order to be eligible: they needed to be at least eighteen years old, clinically diagnosed with AA, AT, or AU (which is defined as scalp hair loss exceeding ninety percent), and their disease needed to be stable or worsening for at least half a year. Clinical and demographic information on each patient was gathered. This information included age, gender, the age at the onset of the disease, the duration of the current episode of the disease, and the severity of AA as assessed by the Severity of Alopecia Tool (SALT).Results: The current sample's average age was 28 years. Males made up half of them (50%). In the current study, the regrowth rate was 74.00%. The re-growth rate showed a positive correlation with age at first episode onset (r=0.24; 0.036) and tofacitinib duration (r=0.43; 0.001), but a negative correlation with current episode duration (r=-0.34; 0.012) and disease duration from first onset (r=-0.15; 0.023).Conclusion: In the current study, a good regeneration rate was seen in more than half of the patients we looked at.The regrowth rate had a negative correlation with the length of the present episode and the time since the disease's onset, and a positive correlation with the age at the beginning of the first episode and the duration of tofacitinib.